.Attributes Medication, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin caused boosted progression-free and general survival, triggering FDA commendation and a new procedure option for people.